T h i s i s S c i e n c e B r a n d i n g ™

T h i s i s w h a t w e d o .

Diovan Case S tudy

T h i s i s w h a t w e d o .

T h i s i s S c i e n c e B r a n d i n g ™

Va l u e o f t h o u g h t l e a d e r r e l a t i o n s h i p s

C u s t o m i z e d , U n i q u e S o l u t i o n s

S t r a t e g i c p o s i t i o n i n g w i t h i n t h e s c i e n c e

Making very complicated science understandable

Exanta Case S tudy

T h i s i s w h a t w e d o .

“Relaunching” a second-in-class product by uncovering new science

Digging further into the science, we and discovered a strong case for dividing its target (the AT receptor)

into a “Good guy” (AT1) and a “Bad guy” (AT2)

Based upon bench science, we were able to make the claim that Diovan blocked AT2 but spared AT1 giving it a double benefit.